Sachin Sarcoma Society
Patient information leaflet for Pazopanib

Patient information leaflet for Pazopanib

Pazopanib is a targeted therapy. Pazopanib is classified as a tyrosine kinase inhibitor vascular endothelial growth factor (VEGF) inhibitor.

Pazopanib is used for the treatment of advanced renal cell carcinoma and soft tissue sarcoma.

The amount of pazopanib that you will receive depends on many factors including your general health or other health problems and the type of cancer or condition you have. Your doctor will determine your exact pazopanib dosage and schedule.

  • Pazopanib is given in tablet form to be taken by mouth on an empty stomach, at least one hour before or two hours after eating

The following Pazopanib side effects are common (occurring in greater than 30%) for patients taking Pazopanib (all grade)

  • Diarrhea Hypertension
  • Hair color changes
  • Low blood counts (low white blood cells, low platelets)
  • Elevated liver function tests (AST ALT)
  • Elevated bilirubin level
  • Blood test abnormalities (low phosphorus, low sodium increased glucose)

These are less common side effects (occurring in 10-29%) for patients receiving Pazopanib

  • Nausea
  • Vomiting
  • Poor appetite
  • Fatigue
  • Weakness
  • Abdominal pain
  • Headache Blood test abnormalities
    • Low Magnesium
    • Low Glucose – Low Blood Sugar

This list includes common and less common side effects for those taking Pazopanib. Pazopanib side effects that are very rare – occurring in less than about 10 percent of patients are not listed here. Always inform your health care provider if you experience any unusual symptoms.

Grade 3 -4 toxicities are (Clinically significant)

Fatigue – 13%

Hypertension and diarrhoea- less than 7%

We recommend BP monitoring once in 4 days for initial 2 months. Besides, Indian patients have more of hand foot syndrome so hands should be kept moist by applying cream. Wear soft shoes.

In case of other queries please see our team.

Pantoprazole should be avoided in patients who take Pazopanib. It causes decrease in effectiveness.